$SCYX
SCYNEXIS Inc

2021 Q3 Form 10-Q Financial Statement

#000156459021056171 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $516.0K $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue $145.0K
YoY Change
Gross Profit $371.0K
YoY Change
Gross Profit Margin 71.9%
Selling, General & Admin $15.41M $3.480M $3.357M
YoY Change 342.84% 40.32% 20.8%
% of Gross Profit 4153.91%
Research & Development $4.401M $8.030M $8.469M
YoY Change -45.19% -13.43% -0.06%
% of Gross Profit 1186.25%
Depreciation & Amortization $48.00K $30.00K $20.00K
YoY Change 60.0% 0.0% -33.33%
% of Gross Profit 12.94%
Operating Expenses $19.81M $11.51M $11.83M
YoY Change 72.13% -2.09% 5.09%
Operating Profit -$19.44M -$11.83M
YoY Change 5.63%
Interest Expense $18.79M $12.44M $319.0K
YoY Change 51.01% 6028.08% 52.63%
% of Operating Profit
Other Income/Expense, Net $18.79M $12.42M $2.301M
YoY Change 51.26% 225.56% -17.62%
Pretax Income -$655.0K $909.0K -$9.525M
YoY Change -172.06% -111.45% 13.35%
Income Tax -$50.00K $0.00 -$3.144M
% Of Pretax Income 0.0%
Net Earnings -$605.0K $909.0K -$6.381M
YoY Change -166.56% -111.45% -24.06%
Net Earnings / Revenue -117.25%
Basic Earnings Per Share -$0.02 $0.09 -$0.64
Diluted Earnings Per Share -$0.06 -$0.28 -$0.64
COMMON SHARES
Basic Shares Outstanding 26.62M 10.63M 10.01M
Diluted Shares Outstanding 27.75M 13.39M 10.01M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $100.1M $29.50M $37.60M
YoY Change 239.35% 4.98% 6.82%
Cash & Equivalents $100.1M $29.50M $34.00M
Short-Term Investments $0.00 $3.600M
Other Short-Term Assets $369.0K $442.0K $863.0K
YoY Change -16.52% 766.67% 1469.09%
Inventory $631.0K
Prepaid Expenses
Receivables $29.00K
Other Receivables $0.00
Total Short-Term Assets $103.9M $32.30M $40.57M
YoY Change 221.77% 11.38% 12.24%
LONG-TERM ASSETS
Property, Plant & Equipment $3.015M $326.0K $354.0K
YoY Change 824.85% -91.19% -23.04%
Goodwill
YoY Change
Intangibles $1.145M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.789M $1.100M $812.0K
YoY Change 62.64% -8.33% 0.0%
Total Long-Term Assets $5.949M $4.500M $4.700M
YoY Change 32.2% -6.25% -4.68%
TOTAL ASSETS
Total Short-Term Assets $103.9M $32.30M $40.57M
Total Long-Term Assets $5.949M $4.500M $4.700M
Total Assets $109.9M $36.80M $45.27M
YoY Change 198.59% 8.88% 10.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.510M $5.300M $4.853M
YoY Change 41.7% -8.62% 27.51%
Accrued Expenses $4.608M $3.004M $2.387M
YoY Change 53.4% 30.61% -30.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $13.22M $8.300M $7.316M
YoY Change 59.28% 2.47% 0.94%
LONG-TERM LIABILITIES
Long-Term Debt $39.38M $13.30M $18.30M
YoY Change 196.12%
Other Long-Term Liabilities $2.099M $5.600M $13.40M
YoY Change -62.52% -20.0% 52.27%
Total Long-Term Liabilities $2.099M $18.90M $31.70M
YoY Change -88.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.22M $8.300M $7.316M
Total Long-Term Liabilities $2.099M $18.90M $31.70M
Total Liabilities $72.27M $27.20M $38.93M
YoY Change 165.69% -1.71% 437.17%
SHAREHOLDERS EQUITY
Retained Earnings -$330.2M -$283.9M -$284.8M
YoY Change 16.31% 10.48%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.61M $9.558M $6.333M
YoY Change
Total Liabilities & Shareholders Equity $109.9M $36.80M $45.27M
YoY Change 198.59% 8.82% 10.14%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$605.0K $909.0K -$6.381M
YoY Change -166.56% -111.45% -24.06%
Depreciation, Depletion And Amortization $48.00K $30.00K $20.00K
YoY Change 60.0% 0.0% -33.33%
Cash From Operating Activities -$16.59M -$9.870M -$8.850M
YoY Change 68.04% -5.1% 14.05%
INVESTING ACTIVITIES
Capital Expenditures -$338.0K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $3.570M $10.67M
YoY Change -100.0% -950.0% 6.49%
Cash From Investing Activities -$338.0K $3.570M $10.66M
YoY Change -109.47% -950.0% 6.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.533M 1.770M 11.96M
YoY Change 156.1% -45.37% 204.33%
NET CHANGE
Cash From Operating Activities -16.59M -9.870M -8.850M
Cash From Investing Activities -338.0K 3.570M 10.66M
Cash From Financing Activities 4.533M 1.770M 11.96M
Net Change In Cash -12.39M -4.530M 13.77M
YoY Change 173.53% -40.24% 122.46%
FREE CASH FLOW
Cash From Operating Activities -$16.59M -$9.870M -$8.850M
Capital Expenditures -$338.0K $0.00 $0.00
Free Cash Flow -$16.25M -$9.870M -$8.850M
YoY Change 64.62% -5.1% 14.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
33592000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
65000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13220000
CY2021Q3 scyx Warrant Liabilities Current
WarrantLiabilitiesCurrent
1037000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2099000
CY2021Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
28579000
CY2020Q4 scyx Warrant Liabilities Current
WarrantLiabilitiesCurrent
17564000
CY2021Q3 scyx Convertible Debt And Derivative Liability
ConvertibleDebtAndDerivativeLiability
10805000
CY2020Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
0
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3274000
CY2020Q4 us-gaap Liabilities
Liabilities
79778000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4608000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1145000
CY2021Q3 us-gaap Assets
Assets
109882000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2850000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7510000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4639000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4141000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2999000
CY2020Q4 us-gaap Assets
Assets
102536000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
52000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26396000
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
14298000
CY2020Q4 scyx Convertible Debt And Derivative Liability
ConvertibleDebtAndDerivativeLiability
16516000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3267000
CY2021Q3 us-gaap Liabilities
Liabilities
72268000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23885570
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23885570
CY2021Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
27000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
367823000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-330236000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
37614000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109882000
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-18810000
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7786000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.68
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
scyx Cost Of Product Revenues
CostOfProductRevenues
145000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19663698
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19663698
CY2020Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
20000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
349351000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326613000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22758000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
102536000
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y10M2D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y7M2D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y10M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M12D
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12566000
scyx Cost Of Product Revenues
CostOfProductRevenues
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16083000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26364000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34879000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9448000
us-gaap Operating Expenses
OperatingExpenses
51107000
us-gaap Operating Expenses
OperatingExpenses
35812000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38541000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35812000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2725000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-806000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
937000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
910000
us-gaap Interest Income Other
InterestIncomeOther
20000
us-gaap Interest Income Other
InterestIncomeOther
188000
us-gaap Interest Expense
InterestExpense
1678000
us-gaap Interest Expense
InterestExpense
859000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
386000
CY2021Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
CY2020Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
20000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
602000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-35378000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15172265
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-16114000
CY2021Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1400000
CY2020Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
5290000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1772000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
6683000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18786000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12420000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31830000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20194000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-655000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
909000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6711000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15618000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-50000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3088000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3144000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-605000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
909000
us-gaap Net Income Loss
NetIncomeLoss
-3623000
us-gaap Net Income Loss
NetIncomeLoss
-12474000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26616628
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10627618
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26147658
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10129098
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27754828
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13389014
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26326006
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11220802
us-gaap Profit Loss
ProfitLoss
-3623000
us-gaap Profit Loss
ProfitLoss
-12474000
us-gaap Depreciation
Depreciation
133000
us-gaap Depreciation
Depreciation
82000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1528000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1220000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
937000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
910000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-35378000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-16114000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1772000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
6683000
scyx Noncash Operating Lease Expenses For Right Of Use Asset
NoncashOperatingLeaseExpensesForRightOfUseAsset
149000
scyx Noncash Operating Lease Expenses For Right Of Use Asset
NoncashOperatingLeaseExpensesForRightOfUseAsset
144000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2725000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-806000
scyx Noncash Consideration Associated With Common Stock Purchase Agreement
NoncashConsiderationAssociatedWithCommonStockPurchaseAgreement
0
scyx Noncash Consideration Associated With Common Stock Purchase Agreement
NoncashConsiderationAssociatedWithCommonStockPurchaseAgreement
602000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1271000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1482000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4990000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2757000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29040000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32782000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
20713000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
589000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
0
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
14235000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-589000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6474000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8027000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4702000
scyx Payments Of Offering Costs And Underwriting Discounts And Commissions
PaymentsOfOfferingCostsAndUnderwritingDiscountsAndCommissions
151000
scyx Payments Of Offering Costs And Underwriting Discounts And Commissions
PaymentsOfOfferingCostsAndUnderwritingDiscountsAndCommissions
279000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
30000000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
1253000
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
22000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
28000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
75000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
10000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
494000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36642000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13882000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7013000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-12426000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93314000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42193000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100327000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29767000
us-gaap Interest Paid Net
InterestPaidNet
1569000
us-gaap Interest Paid Net
InterestPaidNet
840000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
18000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
186000
us-gaap Stock Issued1
StockIssued1
7452000
us-gaap Stock Issued1
StockIssued1
2784000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
556000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
scyx Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
50000
scyx Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
54000
scyx Deferred Offering Costs Reclassified To Additional Paid In Capital
DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital
30000
scyx Deferred Offering Costs Reclassified To Additional Paid In Capital
DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital
1000
scyx Common Stock Issued For Commitment Shares
CommonStockIssuedForCommitmentShares
0
scyx Common Stock Issued For Commitment Shares
CommonStockIssuedForCommitmentShares
602000
scyx Reclass Of Warrant Liability To Additional Paid In Capital
ReclassOfWarrantLiabilityToAdditionalPaidInCapital
298000
scyx Reclass Of Warrant Liability To Additional Paid In Capital
ReclassOfWarrantLiabilityToAdditionalPaidInCapital
0
scyx Reclass Of Deferred Asset Issuance Of Loan Payable To Debt Discount
ReclassOfDeferredAssetIssuanceOfLoanPayableToDebtDiscount
390000
scyx Reclass Of Deferred Asset Issuance Of Loan Payable To Debt Discount
ReclassOfDeferredAssetIssuanceOfLoanPayableToDebtDiscount
0
scyx Settlement Of Liability For Exercise Of Warrants
SettlementOfLiabilityForExerciseOfWarrants
805000
scyx Settlement Of Liability For Exercise Of Warrants
SettlementOfLiabilityForExerciseOfWarrants
0
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-330200000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100100000
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
us-gaap Net Income Loss
NetIncomeLoss
-3623000
us-gaap Net Income Loss
NetIncomeLoss
-12474000
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0
CY2021Q3 scyx Dilutive Securities Effect On Basic Earnings Per Share Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareWarrantLiability
0
CY2020Q3 scyx Dilutive Securities Effect On Basic Earnings Per Share Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareWarrantLiability
-4649000
scyx Dilutive Securities Effect On Basic Earnings Per Share Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareWarrantLiability
-15719000
scyx Dilutive Securities Effect On Basic Earnings Per Share Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareWarrantLiability
-2917000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1593000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3740000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19342000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15391000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26616628
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10627618
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26147658
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10129098
CY2021Q3 scyx Incremental Common Shares Attributable To Stock Options And Restricted Stock Units
IncrementalCommonSharesAttributableToStockOptionsAndRestrictedStockUnits
0
CY2020Q3 scyx Incremental Common Shares Attributable To Stock Options And Restricted Stock Units
IncrementalCommonSharesAttributableToStockOptionsAndRestrictedStockUnits
1058
scyx Incremental Common Shares Attributable To Stock Options And Restricted Stock Units
IncrementalCommonSharesAttributableToStockOptionsAndRestrictedStockUnits
0
scyx Incremental Common Shares Attributable To Stock Options And Restricted Stock Units
IncrementalCommonSharesAttributableToStockOptionsAndRestrictedStockUnits
0
CY2021Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1138200
CY2020Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2021Q3 scyx Incremental Common Shares Attributable To Warrant Liabilities
IncrementalCommonSharesAttributableToWarrantLiabilities
0
CY2020Q3 scyx Incremental Common Shares Attributable To Warrant Liabilities
IncrementalCommonSharesAttributableToWarrantLiabilities
2760338
scyx Incremental Common Shares Attributable To Warrant Liabilities
IncrementalCommonSharesAttributableToWarrantLiabilities
178348
scyx Incremental Common Shares Attributable To Warrant Liabilities
IncrementalCommonSharesAttributableToWarrantLiabilities
1091704
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27754828
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13389014
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26326006
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11220802
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20473931
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6594117
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7741317
CY2021Q3 scyx Prepaid Researchand Development Expenses Current
PrepaidResearchandDevelopmentExpensesCurrent
832000
CY2020Q4 scyx Prepaid Researchand Development Expenses Current
PrepaidResearchandDevelopmentExpensesCurrent
1535000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
798000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
362000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1165000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
19000
CY2021Q3 us-gaap Other Receivables
OtherReceivables
0
CY2020Q4 us-gaap Other Receivables
OtherReceivables
2876000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
369000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
373000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3164000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5165000
CY2021Q3 scyx Accrued Researchand Development Expense Current
AccruedResearchandDevelopmentExpenseCurrent
950000
CY2020Q4 scyx Accrued Researchand Development Expense Current
AccruedResearchandDevelopmentExpenseCurrent
991000
CY2021Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1512000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2190000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2146000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
960000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4608000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4141000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20737000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
9263000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2021Q3 scyx Debt Instrument Final Fee Due At Maturity
DebtInstrumentFinalFeeDueAtMaturity
1185000
CY2021Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
31185000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2606000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
28579000
us-gaap Operating Lease Cost
OperatingLeaseCost
498000
us-gaap Operating Lease Cost
OperatingLeaseCost
498000
CY2021Q3 scyx Variable Lease Cost And Income
VariableLeaseCostAndIncome
9000
CY2020Q3 scyx Variable Lease Cost And Income
VariableLeaseCostAndIncome
9000
scyx Variable Lease Cost And Income
VariableLeaseCostAndIncome
18000
scyx Variable Lease Cost And Income
VariableLeaseCostAndIncome
36000
CY2021Q3 us-gaap Lease Cost
LeaseCost
175000
CY2020Q3 us-gaap Lease Cost
LeaseCost
175000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
174000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
527000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
715000
us-gaap Lease Cost
LeaseCost
516000
us-gaap Lease Cost
LeaseCost
534000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
116000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
114000
us-gaap Operating Lease Payments
OperatingLeasePayments
343000
us-gaap Operating Lease Payments
OperatingLeasePayments
336000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
730000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
744000
CY2021Q3 scyx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
2789000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5679000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3332000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
65000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3267000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3332000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2347000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
588000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23885570
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23885570
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19663698
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19663698
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
32320000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
9000
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
9558000
us-gaap Net Income Loss
NetIncomeLoss
-12474000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
13000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5301000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-3000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
37614000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22758000
us-gaap Net Income Loss
NetIncomeLoss
-3623000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1528000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
22000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8713000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-3000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
766000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
37614000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
6333000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
909000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
399000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1909000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1220000
scyx Stock Issued During Period Value Employee Stock Purchase Plan And Stock Option Plans
StockIssuedDuringPeriodValueEmployeeStockPurchasePlanAndStockOptionPlans
28000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4578000
scyx Stock Issued During Period Value Commitment Shares
StockIssuedDuringPeriodValueCommitmentShares
602000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-75000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
9558000
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-18800000
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7800000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-35400000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-16100000
CY2021Q3 scyx Fair Value Of Liabilities
FairValueOfLiabilities
15300000
CY2020Q4 scyx Fair Value Of Liabilities
FairValueOfLiabilities
51200000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
830343
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.52
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
96000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
838750
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
25587
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1643506
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.52
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
674795
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
24.03
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1643506
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.52
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
10000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
600000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1200000
CY2021Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2020Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
588000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
399000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1528000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1220000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
scyx Contract With Customer Liability Provision Related To Current Period Revenue
ContractWithCustomerLiabilityProvisionRelatedToCurrentPeriodRevenue
1896000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-403000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1493000

Files In Submission

Name View Source Status
0001564590-21-056171-index-headers.html Edgar Link pending
0001564590-21-056171-index.html Edgar Link pending
0001564590-21-056171.txt Edgar Link pending
0001564590-21-056171-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
scyx-10q_20210930.htm Edgar Link pending
scyx-10q_20210930_htm.xml Edgar Link completed
scyx-20210930.xsd Edgar Link pending
scyx-20210930_cal.xml Edgar Link unprocessable
scyx-20210930_def.xml Edgar Link unprocessable
scyx-20210930_lab.xml Edgar Link unprocessable
scyx-20210930_pre.xml Edgar Link unprocessable
scyx-ex311_10.htm Edgar Link pending
scyx-ex312_6.htm Edgar Link pending
scyx-ex321_9.htm Edgar Link pending
Show.js Edgar Link pending